Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/50569
AN IMMUNOMICS APPROACH TO SCHISTOSOME ANTIGEN DISCOVERY: ANTIBODY SIGNATURES OF NATURALLY RESISTANT AND CHRONICALLY INFECTED INDIVIDUALS FROM ENDEMIC AREAS
Autor(es)
Jangola, Soraya Torres Gaze
Driguez, Patrick
Pearson, Mark S.
Mendes, Tiago
Doolan, Denise L.
Trieu, Angela
McManus, Donald P.
Gobert, Geoffrey N.
Periago, Maria Victoria
Oliveira, Rodrigo Correa de
Cardoso, Fernanda C.
Oliveira, Guilherme Corrêa de
Nakajima, Rie
Jasinskas, Al
Hung, Chris
Liang, Li
Pablo, Jozelyn
Bethony, Jeffrey Michael
Felgner, Philip L.
Loukas, Alex
Driguez, Patrick
Pearson, Mark S.
Mendes, Tiago
Doolan, Denise L.
Trieu, Angela
McManus, Donald P.
Gobert, Geoffrey N.
Periago, Maria Victoria
Oliveira, Rodrigo Correa de
Cardoso, Fernanda C.
Oliveira, Guilherme Corrêa de
Nakajima, Rie
Jasinskas, Al
Hung, Chris
Liang, Li
Pablo, Jozelyn
Bethony, Jeffrey Michael
Felgner, Philip L.
Loukas, Alex
Afiliação
Centre for Biodiscovery and Molecular Development of Therapeutics. Australian Institute of Tropical Health and Medicine. Queensland Tropical Health Alliance Laboratory. James Cook University. Cairns, Queensland, Australia/ Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
Centre for Biodiscovery and Molecular Development of Therapeutics. Australian Institute of Tropical Health and Medicine. Queensland Tropical Health Alliance Laboratory. James Cook University. Cairns, Queensland, Australia
Federal University of Minas Gerais. Belo Horizonte, MG, Brazil
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
QIMR Berghofer Medical Research Institute, Brisbane. Queensland, Australia/ Institute for Molecular Biosciences. The University of Queensland. St Lucia, Queensland, Australia
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
University of California Irvine, Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
University of California Irvine,.Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
George Washington University. Washington, D.C., United States of America
University of California Irvine, Irvine, California, United States of America
Centre for Biodiscovery and Molecular Development of Therapeutics. Australian Institute of Tropical Health and Medicine. Queensland Tropical Health /Alliance Laboratory. James Cook University, Cairns. Queensland, Australia
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
Centre for Biodiscovery and Molecular Development of Therapeutics. Australian Institute of Tropical Health and Medicine. Queensland Tropical Health Alliance Laboratory. James Cook University. Cairns, Queensland, Australia
Federal University of Minas Gerais. Belo Horizonte, MG, Brazil
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
QIMR Berghofer Medical Research Institute. Brisbane, Queensland, Australia
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
QIMR Berghofer Medical Research Institute, Brisbane. Queensland, Australia/ Institute for Molecular Biosciences. The University of Queensland. St Lucia, Queensland, Australia
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais. Manaus, AM, Brasil/ Fundação Oswaldo Cruz. Centro de Pesquisas René RachouBelo Horizonte, MG, Brazil
University of California Irvine, Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
University of California Irvine,.Irvine, California, United States of America
University of California Irvine. Irvine, California, United States of America
George Washington University. Washington, D.C., United States of America
University of California Irvine, Irvine, California, United States of America
Centre for Biodiscovery and Molecular Development of Therapeutics. Australian Institute of Tropical Health and Medicine. Queensland Tropical Health /Alliance Laboratory. James Cook University, Cairns. Queensland, Australia
Resumo em Inglês
Schistosomiasis is a neglected tropical disease that is responsible for almost 300,000 deaths annually. Mass drug administration (MDA) is used worldwide for the control of schistosomiasis, but chemotherapy fails to prevent reinfection with schistosomes, so MDA alone is not sufficient to eliminate the disease, and a prophylactic vaccine is required. Herein, we take advantage of recent advances in systems biology and longitudinal studies in schistosomiasis endemic areas in Brazil to pilot an immunomics approach to the discovery of schistosomiasis vaccine antigens. We selected mostly surface-derived proteins, produced them using an in vitro rapid translation system and then printed them to generate the first protein microarray for a multi-cellular pathogen. Using well-established Brazilian cohorts of putatively resistant (PR) and chronically infected (CI) individuals stratified by the intensity of their S. mansoni infection, we probed arrays for IgG subclass and IgE responses to these antigens to detect antibody signatures that were reflective of protective vs. non-protective immune responses. Moreover, probing for IgE responses allowed us to identify antigens that might induce potentially deleterious hypersensitivity responses if used as subunit vaccines in endemic populations. Using multi-dimensional cluster analysis we showed that PR individuals mounted a distinct and robust IgG1 response to a small set of newly discovered and well-characterized surface (tegument) antigens in contrast to CI individuals who mounted strong IgE and IgG4 responses to many antigens. Herein, we show the utility of a vaccinomics approach that profiles antibody responses of resistant individuals in a high-throughput multiplex approach for the identification of several potentially protective and safe schistosomiasis vaccine antigens
Compartilhar